Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Item
http://www.wikidata.org/entity/Q44201082
Towards personalised therapy for von Willebrand disease: a future role for recombinant productsSuccessful aortic aneurysm repair in a woman with severe von Willebrand (type 3) disease.Treatment of patients with von Willebrand disease.Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.Evidence-based recommendations on the treatment of von Willebrand disease in Italy.Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.The management of patients with congenital von Willebrand disease during surgery or other invasive procedures: focus on antihemophilic factor/von Willebrand factor complex.The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.Current management of patients with severe von Willebrand disease type 3: a 2012 update.Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.A single-centre study of haemostatic outcomes of joint replacement in von Willebrand disease and control patients and an analysis of the literature.Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
P2860

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Item
http://www.wikidata.org/entity/Q44201082
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Clinical efficacy of highly pu ...... retrospective clinical study.
@en
Clinical efficacy of highly pu ...... retrospective clinical study.
@nl
type
label
Clinical efficacy of highly pu ...... retrospective clinical study.
@en
Clinical efficacy of highly pu ...... retrospective clinical study.
@nl
prefLabel
Clinical efficacy of highly pu ...... retrospective clinical study.
@en
Clinical efficacy of highly pu ...... retrospective clinical study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Clinical efficacy of highly pu ...... retrospective clinical study.
@en
P2093
P2860
P304
P31
P356
10.1046/J.1365-2516.2002.00688.X
P433
P478
P577
P698